Citizens Financial Group’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $936K | Buy |
21,934
+2,797
| +15% | +$152K | 0.01% | 469 |
|
|
2026
Q1 | $1.2M | Buy |
19,137
+2,617
| +16% | +$209K | 0.02% | 360 |
|
|
2025
Q4 | $1.58M | Buy |
16,520
+430
| +3% | +$42.2K | 0.02% | 313 |
|
|
2025
Q3 | $1.57M | Buy |
16,090
+1,930
| +14% | +$200K | 0.02% | 319 |
|
|
2025
Q2 | $1.52M | Buy |
14,160
+3,675
| +35% | +$372K | 0.02% | 288 |
|
|
2025
Q1 | $1.06M | Buy |
10,485
+1,515
| +17% | +$153K | 0.02% | 313 |
|
|
2024
Q4 | $801K | Buy |
8,970
+3,931
| +78% | +$346K | 0.02% | 325 |
|
|
2024
Q3 | $422K | Buy |
5,039
+1,475
| +41% | +$116K | 0.01% | 406 |
|
|
2024
Q2 | $274K | Buy |
+3,564
| New | +$261K | 0.01% | 460 |
|
|
2022
Q1 | – | Sell |
-4,995
| Closed | -$212K | – | 444 |
|
|
2021
Q4 | $212K | Sell |
4,995
-578
| -10% | -$24.3K | 0.01% | 424 |
|
|
2021
Q3 | $242K | Hold |
5,573
| – | – | 0.01% | 400 |
|
|
2021
Q2 | $238K | Sell |
5,573
-1,593
| -22% | -$67K | 0.01% | 327 |
|
|
2021
Q1 | $277K | Hold |
7,166
| – | – | 0.01% | 260 |
|
|
2020
Q4 | $258K | Sell |
7,166
-1,780
| -20% | -$64.2K | 0.01% | 259 |
|
|
2020
Q3 | $342K | Sell |
8,946
-2,611
| -23% | -$101K | 0.02% | 200 |
|
|
2020
Q2 | $406K | Sell |
11,557
-1,783
| -13% | -$64.2K | 0.03% | 207 |
|
|
2020
Q1 | $435K | Sell |
13,340
-2,592
| -16% | -$101K | 0.04% | 195 |
|
|
2019
Q4 | $720K | Sell |
15,932
-676
| -4% | -$28.3K | 0.05% | 161 |
|
|
2019
Q3 | $676K | Sell |
16,608
-608
| -4% | -$25.8K | 0.05% | 154 |
|
|
2019
Q2 | $740K | Sell |
17,216
-201,078
| -92% | -$7.73M | 0.05% | 148 |
|
|
2019
Q1 | $8.38M | Buy |
218,294
+800
| +0.4% | +$30.6K | 0.62% | 56 |
|
|
2018
Q4 | $7.69M | Sell |
217,494
-942
| -0.4% | -$34.2K | 0.7% | 56 |
|
|
2018
Q3 | $8.41M | Sell |
218,436
-4,380
| -2% | -$153K | 0.66% | 56 |
|
|
2018
Q2 | $7.29M | Sell |
222,816
-6,626
| -3% | -$200K | 0.61% | 58 |
|
|
2018
Q1 | $6.27M | Sell |
229,442
-9,095
| -4% | -$247K | 0.53% | 70 |
|
|
2017
Q4 | $5.91M | Buy |
238,537
+6,237
| +3% | +$172K | 0.48% | 72 |
|
|
2017
Q3 | $6.78M | Sell |
232,300
-10,620
| -4% | -$293K | 0.58% | 63 |
|
|
2017
Q2 | $6.73M | Sell |
242,920
-10,689
| -4% | -$284K | 0.6% | 67 |
|
|
2017
Q1 | $6.31M | Sell |
253,609
-93,510
| -27% | -$2.27M | 0.56% | 68 |
|
|
2016
Q4 | $7.51M | Sell |
347,119
-16,990
| -5% | -$371K | 0.73% | 54 |
|
|
2016
Q3 | $8.67M | Sell |
364,109
-192
| -0.1% | -$4.58K | 0.82% | 50 |
|
|
2016
Q2 | $8.51M | Sell |
364,301
-5,958
| -2% | -$129K | 0.82% | 49 |
|
|
2016
Q1 | $6.96M | Sell |
370,259
-120,307
| -25% | -$2.11M | 0.67% | 61 |
|
|
2015
Q4 | $9.06M | Buy |
+490,566
| New | +$8.79M | 0.86% | 45 |
|
Other funds holding BSX
Citizens Financial Group's BSX Position: Q2 2026 in Review
Citizens Financial Group increased its Boston Scientific (BSX) stake by 15% in Q2 2026, buying an estimated $152K and bringing the position to 21,934 shares worth $936K. The position accounts for 0.01% of the portfolio, ranked #469.
Citizens Financial Group first reported a position in BSX in Q4 2015 and has held it in 34 quarters since. The position peaked at $9.06M in Q4 2015. 1,470 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Citizens Financial Group held 21,934 shares of Boston Scientific worth $936K as of Q2 2026.
- Citizens Financial Group bought 2,797 Boston Scientific shares in Q2 2026, an estimated $152K.
- Boston Scientific made up 0.01% of Citizens Financial Group's portfolio in Q2 2026, its #469 holding.
- Citizens Financial Group first reported a position in Boston Scientific in Q4 2015 and has held it in 34 quarters since.
- Citizens Financial Group's Boston Scientific position peaked at $9.06M in Q4 2015.
- 1,470 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Citizens Financial Group's 13F filing for Q2 2026, filed 7 Aug 2026.